TNF Pharmaceuticals Licenses LightSolver's Compute Accelerator Tech for Innovative Therapies.

TNF Pharmaceuticals has entered into a licensing agreement with LightSolver for their innovative compute accelerator technology. The biopharmaceutical company focuses on developing novel therapies for age-related diseases, autoimmune, and inflammatory conditions through two therapeutic platforms: MYMD-1 and Supera-CBD. MYMD-1 regulates the immune system to control TNF-a, while Supera-CBD is a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy.

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) has entered into a licensing agreement with LightSolver Ltd. to utilize the company's innovative light-speed computing accelerator technology. This strategic partnership aims to revolutionize cryptocurrency applications by significantly reducing energy costs and enhancing computational efficiency.

LightSolver, recognized as a 2025 World Economic Forum Technology Pioneer and a sample vendor in Gartner’s 2025 Hype Cycle for Data Center Infrastructure Technologies, has developed the first laser-based processing unit (LPU) designed to outperform quantum and supercomputing technologies. The LPU harnesses light for computation, offering an accelerated method to solve complex problems at the speed of light.

TNF Pharmaceuticals, under the leadership of Executive Chairman Joshua Silverman, has secured exclusive rights to use LightSolver’s LPU technology in cryptocurrency and blockchain applications. The company intends to change its name to reflect this new venture. TNF Pharmaceuticals aims to leverage this technology to create a more sustainable cryptocurrency infrastructure.

The partnership also involves a $7.0 million private placement financing, with TNF’s largest stockholder and other existing stockholders participating in the sale of 7,000 shares of its newly created Series H convertible preferred stock. The transaction is expected to close on or about September 4, 2025, subject to customary closing conditions.

TNF Pharmaceuticals, which focuses on developing novel therapies for age-related diseases, autoimmune, and inflammatory conditions through its MYMD-1 and Supera-CBD platforms, sees this partnership as an opportunity to capitalize on the growing momentum behind photonic computing and the future of cryptocurrency infrastructure. The company believes it has secured first-mover advantages in a burgeoning industry, positioning itself for growth and value creation.

References:
[1] https://www.businesswire.com/news/home/20250902945912/en/TNF-Pharmaceuticals-Secures-Exclusive-Global-Rights-to-Innovative-Light-Speed-Computing-Accelerator-for-Use-in-Cryptocurrency-Applications